These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1919630

  • 1. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
    Markman M, Reichman B, Hakes T, Jones W, Lewis JL, Rubin S, Almadrones L, Hoskins W.
    J Clin Oncol; 1991 Oct; 9(10):1801-5. PubMed ID: 1919630
    [Abstract] [Full Text] [Related]

  • 2. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M, Chapman D, Saigo P.
    J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288
    [Abstract] [Full Text] [Related]

  • 3. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
    Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Yordan EL, Eriksson J, Lewis JL.
    J Clin Oncol; 1991 Feb; 9(2):204-10. PubMed ID: 1988569
    [Abstract] [Full Text] [Related]

  • 4. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS, Lele SB, Marchetti DL, Baker TR, Emrich LJ, Hartman AB.
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
    Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB.
    J Clin Oncol; 1991 Apr; 9(4):649-57. PubMed ID: 2066761
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ, Braly P, Leong L, Shibata S, Margolin K, Somlo G, McNamara M, Longmate J, Schinke S, Raschko J, Nagasawa S, Kogut N, Najera L, Johnson D, Doroshow JH.
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [Abstract] [Full Text] [Related]

  • 7. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W.
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of intraperitoneal cisplatin and thiotepa in residual ovarian carcinoma: a Gynecologic Oncology Group study.
    Feun LG, Blessing JA, Major FJ, DiSaia PJ, Alvarez RD, Berek JS.
    Gynecol Oncol; 1998 Dec; 71(3):410-5. PubMed ID: 9887240
    [Abstract] [Full Text] [Related]

  • 9. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
    Makhija S, Sabbatini P, Aghajanian C, Venkatraman E, Spriggs DR, Barakat R.
    Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
    [Abstract] [Full Text] [Related]

  • 10. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J.
    Acta Obstet Gynecol Scand; 2009 Oct; 88(4):463-7. PubMed ID: 19235559
    [Abstract] [Full Text] [Related]

  • 11. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.
    Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S.
    Semin Oncol; 1991 Feb; 18(1 Suppl 3):5-10. PubMed ID: 2003227
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
    Piver MS, Recio FO, Baker TR, Driscoll D.
    Cancer; 1994 Mar 15; 73(6):1693-8. PubMed ID: 7512437
    [Abstract] [Full Text] [Related]

  • 13. Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
    Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F.
    Ann Surg Oncol; 2014 May 15; 21(5):1468-73. PubMed ID: 24081797
    [Abstract] [Full Text] [Related]

  • 14. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W.
    J Clin Oncol; 1992 Sep 15; 10(9):1479-84. PubMed ID: 1517791
    [Abstract] [Full Text] [Related]

  • 15. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Recio FO, Piver MS, Hempling RE, Driscoll DL.
    Gynecol Oncol; 1998 Mar 15; 68(3):267-73. PubMed ID: 9570979
    [Abstract] [Full Text] [Related]

  • 16. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
    Markman M, Blessing JA, Major F, Manetta A.
    Gynecol Oncol; 1993 Aug 15; 50(2):191-5. PubMed ID: 8375734
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A, Carnino F, Chiara S, Brunetti I, Tanganelli L, Romanini A, Bruzzone M, Conte PF.
    Gynecol Oncol; 2000 Feb 15; 76(2):157-62. PubMed ID: 10637064
    [Abstract] [Full Text] [Related]

  • 18. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ, Shah CA, Swensen RE, Tamimi HK, Goff BA.
    Gynecol Oncol; 2010 Mar 15; 116(3):340-4. PubMed ID: 19922987
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, Horton MC, McVey L, Morris J, Weiss RJ.
    J Clin Oncol; 1990 Jan 15; 8(1):137-45. PubMed ID: 2295904
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr 15; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.